Nuvectis Pharma Inc Income Statement
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
2023
2022
2021
2020
0M
-100.00%
23M
-23M
23M
8M
15M
-23M
0M
-22M
0M
-22M
18.49%
23M
0M
-23M
0M
0M
0M
-
19M
-19M
19M
6M
13M
-19M
0M
-19M
0M
-19M
45.79%
19M
0M
-19M
0M
-19M
0M
-
13M
-13M
13M
3M
10M
-13M
0M
-13M
0M
-13M
128,760.00%
13M
0M
-13M
0M
-13M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
128,760.00%
0M
0M
0M
0M
0M
Concept
Total Revenue
YoY
Cost of Goods Sold (COGS)
Gross Profit
Operating expenses
Selling, General & Administrative
Research & Development
Operating Income
Interest Expense
Income Before Tax
Tax Provision
Net Income
YoY
Total Expenses
Net Interest Income
EBITDA
Reconciled Depreciation
EBIT
4Q2023
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
4Q2021
3Q2021
2Q2021
1Q2021
0M
-100.00%
0M
0M
7M
3M
4M
-7M
0M
-7M
0M
-7M
1.38%
7M
0M
-7M
0M
0M
0M
-
6M
-6M
6M
2M
4M
-6M
0M
-6M
0M
-6M
2.19%
6M
0M
-6M
0M
0M
0M
-
6M
-6M
6M
2M
4M
-6M
0M
-6M
0M
-6M
60.29%
6M
0M
-6M
0M
-6M
4M
-
-4M
4M
4M
2M
2M
-4M
0M
-4M
0M
-4M
36.00%
4M
0M
-4M
0M
-4M
0M
3,625.00%
0M
0M
7M
2M
4M
-7M
0M
-7M
0M
-7M
188.90%
7M
0M
-7M
0M
-7M
0M
-
6M
-6M
6M
1M
5M
-6M
0M
-6M
0M
-6M
23.29%
6M
0M
-6M
0M
-6M
0M
-
4M
-4M
4M
1M
3M
-4M
0M
-4M
0M
-4M
-40.03%
4M
0M
-4M
0M
-4M
0M
-
3M
-3M
3M
1M
2M
-3M
0M
-3M
0M
-3M
12,678.26%
3M
0M
-3M
0M
-3M
0M
-
0M
0M
2M
1M
1M
-2M
0M
-2M
0M
-2M
12,678.26%
2M
0M
-2M
0M
-2M
0M
-
0M
0M
5M
1M
4M
-5M
0M
-5M
0M
-5M
12,678.26%
5M
0M
-5M
0M
-8M
0M
-
0M
0M
6M
2M
4M
-6M
0M
-6M
0M
-6M
12,678.26%
6M
0M
-6M
0M
-2M
0M
-
0M
0M
0M
0M
0M
0M
0M
0M
0M
0M
12,678.26%
0M
0M
0M
0M
0M